| Aug 14 |
Why Serve Robotics Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
|
| Jul 31 |
Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder
|
| Jul 29 |
Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024
|
| Jul 18 |
Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder
|
| May 31 |
Bionomics Limited Announces Private Placement of up to $70.0 Million
|
| May 20 |
Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
|
